Previous 10 | Next 10 |
NEW YORK, July 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended June 30, 2023. Activities Report Cash balance at the end o...
2023-07-25 10:00:00 ET Summary Mesoblast Limited has a PDUFA from a resubmitted BLA in two weeks. The previous adcomm, held over 2 years ago, voted 9-1 for approval on efficacy. The FDA did not agree because it had a problem with manufacturing homogeneity. I haven...
NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory rol...
2023-05-26 03:13:02 ET Mesoblast press release ( NASDAQ: MESO ): Q3 GAAP EPS of -$0.025 beats by $0.13 . Revenue of $1.94M (-3.0% Y/Y) misses by $0.18M . Cash on hand at the end of the quarter of $48.8 million, pro-forma cash after adjusting for $40.0 million o...
2023-05-25 23:38:08 ET Mesoblast Limited (MESO) Q3 2023 Earnings Conference Call May 25, 2023 6:30 PM ET Company Participants Silviu Itescu – Chief Executive Officer Eric Rose – Chief Medical Officer Andrew Chaponnel – Interim Chief Financial...
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2023. OPERATIONAL HIGHLIGHTS Re...
2023-05-04 16:22:41 ET Summary Among lower US-listed biotech stocks on the back of the US banking turmoil, Australia-based regenerative medicine product developer Mesoblast Limited offers upside opportunities to be seized. MESO is targeting the growing cardiovascular disease marke...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareh...
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and ...
2023-03-08 12:54:43 ET Gainers: Kimball International ( KBAL ) +83% . Arlo Technologies ( ARLO ) +45% . Diversey ( DSEY ) +37% . Maxeon ( MAXN ) +32% . LifeStance ( LFST ) +26% . Mesoblast ( MESO ) +26% . Vertex (...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...